Drug Details
General Information of the Drug (ID: DR9742) | ||||
---|---|---|---|---|
Name |
Gefitinib
|
|||
Synonyms |
Iressa; ZD1839; Irressat; gefitinib (zd1839); N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; ZD 1839; ZD-1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; UNII-S65743JHBS; CCRIS 9011; CHEMBL939; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4; 184475-35-2
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Lung cancer [ICD-11: 2C25] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C22H24ClFN4O3
|
|||
PubChem CID | ||||
Canonical SMILES |
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
|
|||
InChI |
1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
|
|||
InChIKey |
XGALLCVXEZPNRQ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 184475-35-2
|
|||
GDSC | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Apigenin | Psilotum nudum | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CYB5R2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CYM | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | HIF-1A | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | PRKAA1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SLC2A1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SLC2A3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SLC2A4 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Down-regulation | Autophagy flux | ||||
Induction | Cell cycle arrest in G0/G1 phase | |||||
In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1alpha, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 Cells. | |||||
Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | ITGAM | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | NDUFA2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
Experimental
Result(s) |
Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. | |||||
Betulinic Acid | Rubus alceifolius | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | RB1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | TYMS | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | Loss of mitochondrial membrane potential | ||||
In-vitro Model | HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Combining betulinic acid with an EGFR TKI improves drug efficacy in EGFR TKI-resistant lung cancer cells. | |||||
Bufalin | Bufo gargarizans | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | MET | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Combination of bufalin and gefitinib potently inhibited the growth of H1975 cells, and induced cell apoptosis. The potential mechanism for anti-tumor might be involved in blocking EGFR-PI3k/Akt pathway. | |||||
Cryptotanshinone | Salvia miltiorrhiza | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | GABPA | Molecule Info | |||
Down-regulation | Expression | TK | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | ||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
In-vivo Model | H1975 human lung cancer cells (5 * 107 in 1 ml) or PC9/GR human lung cancer cells (3 * 107 in 1 ml) were injected subcutaneously into the right flank of athymic BALB/c nude mice (3-4 weeks old). | |||||
Experimental
Result(s) |
Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase. | |||||
Cucurbitacin B | Cucurbitaceae | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
CuB plus Gef treatment caused a significant growth and cell cycle inhibition and induced apoptosis in both cell lines. | |||||
Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | MEK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | MEK2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | PSG1 | Molecule Info | |||
Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | H157 | CVCL_2458 | Mucosa squamous cell carcinoma | Homo sapiens | ||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
In-vivo Model | H157 and H1299 cells (6*106 cells per mouse) were subcutaneously grafted into the right flanks of six-week-old female athymic nude BALBL/c mice. | |||||
Experimental
Result(s) |
Combination treatment with curcumin and gefitinib markedly downregulated EGFR activity through suppressing Sp1 and blocking interaction of Sp1 and HADC1, and markedly suppressed receptor tyrosine kinases as well as ERK/MEK and AKT/S6K pathways in the resistant NSCLC cells. | |||||
Cyclopamine | Veratrum californicum | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
|
In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
Experimental
Result(s) |
The combined cyclopamine and gefitinib were more effective at suppressing the invasiveness of PC3 cells through matrigel in vitro as the drugs alone. | |||||
Elemene | Pogostemon cablin | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [11] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | HES1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | NOTCH1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | SHH | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | SOX2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | TWIST1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | ZEB1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2. | |||||
Genistein | Glycine max | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [12] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | COL11A2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
In-vivo Model | Detached H1975 cells were diluted and emulsified with medium to a final concentration of 2*107 cells/ml. The emulsion (200 uL) was inoculated subcutaneously into 4-6-week-old female nude BALB/c mice. | |||||
Experimental
Result(s) |
Genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of EGFR. | |||||
Luteolin | Abrus precatorius | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [13] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Arrest | Cell cycle arrest in G0/G1 phase | ||||
In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase. | |||||
Metformin | Galega officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [14] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Calu-3 | CVCL_0609 | Lung adenocarcinoma | Homo sapiens | ||
GLC-82 | CVCL_3371 | Non-small cell lung cancer | Homo sapiens | |||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Metformin and gefitinib are synergistic in LKB1 wild-type NSCLC cells. | |||||
Shikonin | Lithospermum erythrorhizon | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [15] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | PKM | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
In-vivo Model | Animal models were constructed by injecting A549 cells (1*107) into nude mice (six-week) in the dorsal area. | |||||
Experimental
Result(s) |
Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway. | |||||
Vitamin E | Salmo salar | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [16] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | NRK-49F | CVCL_2144 | Healthy | Rattus norvegicus | ||
Experimental
Result(s) |
A combined treatment with low-dose gefitinib and vitamin E has synergistic effects that reduce TGF Beta1 induced fibroblast proliferation, cell-cycle arrest and the ERK phosphorylation pathway. | |||||
β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
Cucurbitacin D | Cucurbitaceae | Click to Show/Hide the Molecular Data of This NP | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [17] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
|
In-vitro Model | HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Cucurbitacin D overcomes gefitinib resistance by blocking EGF binding to EGFR and inducing cell death in NSCLCs. | |||||
Sulforaphane | Brassica oleracea | Click to Show/Hide the Molecular Data of This NP | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [18] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
Experimental
Result(s) |
The combination of SFN and gemcitabine potentiates the efficacy of gemcitabine and minimize the toxicity to normal cells. | |||||
γ. A List of Natural Product(s) Able to Reverse the Resistance of This Drug | ||||||
Celastrol | Celastrus strigillosus | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [19] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
In-vivo Model | Each mouse (five-week-old BALB/c nude mice) was subcutaneously injected with 2 * 106 H1975 lung carcinoma cells in logarithmic growth phase. | |||||
Experimental
Result(s) |
Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. | |||||
Epigallocatechin gallate | Hamamelis virginiana | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [20] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
In-vivo Model | A549 cells were injected subcutaneously (1*106, 100 uL of PBS) into the left flanks of the 7-8-week old BALB/C male nude mice. | |||||
Experimental
Result(s) |
EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC. | |||||
Gambogic acid | Garcinia morella | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [21] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | MEK1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
In-vivo Model | The mice were subcutaneously injected with 1*107 NCI-H1975 cells suspended in 100 uL of Matrigel. | |||||
Experimental
Result(s) |
Gefitinib in combination with GA resulted in antitumor growth in the EGFR-T790M secondary mutation NCI-H1975 tumor model due to an enhanced apoptotic effect. | |||||
Silibinin | Carduus marianus | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [22] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
LK2 | CVCL_W132 | Ovarian carcinoma | Homo sapiens | |||
PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
293T GNE | CVCL_0V13 | Healthy | Homo sapiens | |||
In-vivo Model | Animal models were constructed by implanting 5*106 PC-9 cells in Matrigel into the flanks of female severe combined immunodeficiency (SCID) mice. | |||||
Experimental
Result(s) |
Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. | |||||
Triptolide | Tripterygium hypoglaucum | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [23] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
In-vivo Model | The A549/siE-cad cells (2*106) were injected subcutaneously into the underarms of the right forelimbs of 6-week-old BCLB/c mice. | |||||
Experimental
Result(s) |
Triptolide inhibits epithelial mesenchymal transition and induces apoptosis in gefitinib resistant lung cancer cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Epidermal growth factor receptor (EGFR) | Molecule Info | [24] | |
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | Rap1 signaling pathway | |||
5 | Calcium signaling pathway | |||
6 | Cytokine-cytokine receptor interaction | |||
7 | HIF-1 signaling pathway | |||
8 | FoxO signaling pathway | |||
9 | Endocytosis | |||
10 | PI3K-Akt signaling pathway | |||
11 | Dorso-ventral axis formation | |||
12 | Focal adhesion | |||
13 | Adherens junction | |||
14 | Gap junction | |||
15 | Regulation of actin cytoskeleton | |||
16 | GnRH signaling pathway | |||
17 | Estrogen signaling pathway | |||
18 | Oxytocin signaling pathway | |||
19 | Epithelial cell signaling in Helicobacter pylori infection | |||
20 | Hepatitis C | |||
21 | Pathways in cancer | |||
22 | Proteoglycans in cancer | |||
23 | MicroRNAs in cancer | |||
24 | Pancreatic cancer | |||
25 | Endometrial cancer | |||
26 | Glioma | |||
27 | Prostate cancer | |||
28 | Melanoma | |||
29 | Bladder cancer | |||
30 | Non-small cell lung cancer | |||
31 | Central carbon metabolism in cancer | |||
32 | Choline metabolism in cancer | |||
NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
2 | EGFR1 Signaling Pathway | |||
Panther Pathway | Cadherin signaling pathway | Click to Show/Hide | ||
2 | EGF receptor signaling pathway | |||
Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
2 | Signaling events mediated by PTP1B | |||
3 | Arf6 signaling events | |||
4 | Signaling events mediated by TCPTP | |||
5 | Thromboxane A2 receptor signaling | |||
6 | SHP2 signaling | |||
7 | Regulation of Telomerase | |||
8 | EGF receptor (ErbB1) signaling pathway | |||
9 | EGFR-dependent Endothelin signaling events | |||
10 | Posttranslational regulation of adherens junction stability and dissassembly | |||
11 | Direct p53 effectors | |||
12 | ErbB1 downstream signaling | |||
13 | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
14 | E-cadherin signaling in keratinocytes | |||
15 | ErbB receptor signaling network | |||
16 | Internalization of ErbB1 | |||
17 | Stabilization and expansion of the E-cadherin adherens junction | |||
18 | a6b1 and a6b4 Integrin signaling | |||
19 | Syndecan-3-mediated signaling events | |||
Reactome | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | Click to Show/Hide | ||
2 | SHC1 events in ERBB2 signaling | |||
3 | PLCG1 events in ERBB2 signaling | |||
4 | PIP3 activates AKT signaling | |||
5 | GRB2 events in EGFR signaling | |||
6 | GAB1 signalosome | |||
7 | SHC1 events in EGFR signaling | |||
8 | EGFR downregulation | |||
9 | GRB2 events in ERBB2 signaling | |||
10 | PI3K events in ERBB2 signaling | |||
11 | EGFR Transactivation by Gastrin | |||
12 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
13 | Constitutive Signaling by EGFRvIII | |||
14 | RAF/MAP kinase cascade | |||
WikiPathways | ErbB Signaling Pathway | Click to Show/Hide | ||
2 | Regulation of Actin Cytoskeleton | |||
3 | EGF/EGFR Signaling Pathway | |||
4 | MAPK Signaling Pathway | |||
5 | Focal Adhesion | |||
6 | Aryl Hydrocarbon Receptor Pathway | |||
7 | Extracellular vesicle-mediated signaling in recipient cells | |||
8 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
9 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
10 | Bladder Cancer | |||
11 | Hair Follicle Development: Induction (Part 1 of 3) | |||
12 | Signaling by ERBB4 | |||
13 | Signaling by ERBB2 | |||
14 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
15 | PIP3 activates AKT signaling | |||
16 | Nanoparticle-mediated activation of receptor signaling | |||
17 | Aryl Hydrocarbon Receptor | |||
18 | Spinal Cord Injury | |||
19 | Integrated Pancreatic Cancer Pathway | |||
20 | Gastric cancer network 2 | |||
21 | AGE/RAGE pathway | |||
22 | Signaling Pathways in Glioblastoma | |||
23 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
24 | miR-targeted genes in muscle cell - TarBase | |||
25 | miR-targeted genes in lymphocytes - TarBase | |||
26 | miR-targeted genes in epithelium - TarBase | |||
27 | Integrated Breast Cancer Pathway | |||
28 | Signaling by EGFR | |||
29 | L1CAM interactions |